Insider Selling: Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) SVP Sells 43,657 Shares of Stock

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) SVP Jason B. Daly sold 43,657 shares of the company’s stock in a transaction on Friday, November 15th. The shares were sold at an average price of $8.61, for a total transaction of $375,886.77. Following the completion of the sale, the senior vice president now owns 13,665 shares of the company’s stock, valued at approximately $117,655.65. This trade represents a 76.16 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Amneal Pharmaceuticals Stock Performance

Shares of NASDAQ:AMRX traded up $0.11 during trading on Tuesday, reaching $8.44. 706,305 shares of the stock were exchanged, compared to its average volume of 1,405,253. Amneal Pharmaceuticals, Inc. has a 12-month low of $4.16 and a 12-month high of $9.48. The firm’s 50-day moving average price is $8.57 and its 200 day moving average price is $7.68. The firm has a market cap of $2.61 billion, a price-to-earnings ratio of -12.25 and a beta of 1.17.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on AMRX shares. StockNews.com raised Amneal Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Monday, November 11th. Piper Sandler lifted their target price on Amneal Pharmaceuticals from $9.00 to $11.00 and gave the company an “overweight” rating in a research note on Monday, November 11th. Truist Financial upped their price target on Amneal Pharmaceuticals from $10.00 to $12.00 and gave the stock a “buy” rating in a research note on Wednesday, October 2nd. JPMorgan Chase & Co. upgraded shares of Amneal Pharmaceuticals from an “underweight” rating to a “neutral” rating and set a $9.00 price objective on the stock in a research report on Friday, September 6th. Finally, Barclays raised their target price on shares of Amneal Pharmaceuticals from $8.00 to $10.00 and gave the stock an “overweight” rating in a research note on Tuesday, August 13th. One equities research analyst has rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $10.00.

Institutional Investors Weigh In On Amneal Pharmaceuticals

Several large investors have recently made changes to their positions in AMRX. Rothschild Investment LLC acquired a new stake in shares of Amneal Pharmaceuticals in the second quarter worth $26,000. Gladius Capital Management LP acquired a new stake in shares of Amneal Pharmaceuticals in the third quarter worth $37,000. DekaBank Deutsche Girozentrale acquired a new stake in shares of Amneal Pharmaceuticals in the second quarter worth $42,000. Atlanta Consulting Group Advisors LLC acquired a new stake in Amneal Pharmaceuticals during the 1st quarter valued at $61,000. Finally, nVerses Capital LLC acquired a new stake in Amneal Pharmaceuticals during the 2nd quarter valued at $62,000. Institutional investors and hedge funds own 31.82% of the company’s stock.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.